NCT03708744View on ClinicalTrials.gov

A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

November 20, 2018

Study Completion Date

November 20, 2018

Conditions
Migraine
Interventions
DRUG

A: M207 3.8mg, 30 min, upper arm

A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)

DRUG

B: M207 3.8 mg, 30 min, thigh

B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)

DRUG

C: M207 3.8 mg, 1 hr, upper arm

C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)

DRUG

D:zolmitriptan nasal spray

D: 2.5 mg/0.1 mL intranasal zolmitriptan

Trial Locations (1)

07753

Hill Top Research, Inc., Neptune City

All Listed Sponsors
lead

Zosano Pharma Corporation

INDUSTRY

NCT03708744 - A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers | Biotech Hunter | Biotech Hunter